Trademark Overview
On Wednesday, May 28, 2025, a trademark application was filed for XERVYTEG with the United States Patent and Trademark Office. The USPTO has given the XERVYTEG trademark a serial number of 99205147. The federal status of this trademark filing is RESPONSE AFTER NON-FINAL ACTION - ENTERED as of Thursday, September 18, 2025. This trademark is owned by MAAT PHARMA. The XERVYTEG trademark is filed in the Pharmaceutical Products and Medical Instrument Products categories with the following description:
Pharmaceutical and biopharmaceutical products and preparations for medical treatment of gastrointestinal diseases and disorders emanating from microbiota dysfunction, and for treating cancers and diseases, namely, neurological, psychiatric, gastrointestinal, metabolic, inflammatory, autoimmune, and infectious diseases; Pharmaceuticals for treatment, maintaining and restoring human health in the field of disturbed microbial community, and treatment for dysbiosis, cancers, and diseases, in the nature of neurological, psychiatric, gastrointestinal, metabolic, inflammatory, autoimmune, and infectious diseases; Biological preparations in the nature of microorganisms used to treat, maintain and restore human health in the field of treatment of a disturbed microbial community, namely, for the treatment of dysbiosis, cancers, and diseases in the nature of neurological, psychiatric, gastrointestinal, metabolic, inflammatory, autoimmune, and infectious diseases
Medical and surgical apparatus and instruments for use in gastrointestinal surgery; drug delivery devices in the nature of medical apparatus and instruments for administration of pharmaceutical and biopharmaceutical products and preparations, namely, a kit comprising a suspension bag and administration tube set, sold empty; Drug delivery devices to treat gut microbiome-related disorders, cancers, neurological diseases, psychiatric diseases, gastrointestinal diseases, metabolic diseases, inflammatory diseases, autoimmune diseases, infectious diseases, namely, oral delivery capsules, suppositories, syringes, infusion sets, implantable devices sold empty; drug delivery devices to treat gut microbiome-related disorders, cancers, neurological diseases, psychiatric diseases, gastrointestinal diseases, metabolic diseases, inflammatory diseases, autoimmune diseases, infectious diseases, in the nature of a kit comprising a prefilled suspension bag and administration tube set sold without medica...
